, none detailing the clinical status of the patients from which strains were isolated. Our interest in this agent is from the viewpoint of treating skin infections in children (2-5). This has led to a comparison of the activities of cefaclor and cephalothin against 201 strains of staphylococci contained in our collection, approximately half of which were isolated from patients with bullous or other primary forms of staphylococcal skin infection. This comparison was followed by a clinical appraisal of the efficacy of cefaclor in patients with staphylococcal bullous impetigo. The combined laboratory and clinical studies form the basis for the present report.
In vitro susceptibility tests of 201 strains of Staphylococcus aureus by agar dilution revealed 90% to be susceptible to 8 jig or less of cefaclor per ml. Strains from hospitalized children and adults were more often resistant than those from patients with bullous impetigo. Cephalothin was more active than cefaclor against all strains tested. Results with disk tests, including those strains examined from the clinical investigation, revealed some discrepancies in identifying strains more resistant to cefaclor. In clinical studies, cefaclor proved quite effective for the treatment of bullous impetigo. Of 73 patients, 90% were cured and 7% improved after completing 5 or more days of treatment. Prompt improvement was noted among most patients seen 3 to 5 days after treatment was begun. One patient experienced mild diarrhea. There were no other adverse or toxic manifestations attributable to therapy.
Cefaclor is a new orally active cephalosporin.
There are several reports describing in vitro susceptibility of Staphylococcus aureus to this antibiotic (1, 8, 9, 11, 12) , none detailing the clinical status of the patients from which strains were isolated. Our interest in this agent is from the viewpoint of treating skin infections in children (2) (3) (4) (5) . This has led to a comparison of the activities of cefaclor and cephalothin against 201 strains of staphylococci contained in our collection, approximately half of which were isolated from patients with bullous or other primary forms of staphylococcal skin infection. This comparison was followed by a clinical appraisal of the efficacy of cefaclor in patients with staphylococcal bullous impetigo. The combined laboratory and clinical studies form the basis for the present report.
MATERIALS AND METHODS
A total of 201 strains of S. aureus previously isolated and stored either in lyophilized form or at -700C in defibrinated sheep blood were compared for in vitro susceptibility to cefaclor and cephalothin. This total included 106 strains from patients with staphylococcal impetigo, 70 isolated in 1966 and 36 isolated in 1975.
The remaining 95 strains were from hospitalized patients with serious staphylococcal infections; 58 of 95 were from children seen at The Children's Hospital and 37 of 95 were from adults at the University Hospital in Birmingham, Ala. An additional collection of 80 bullous impetigo strains from those patients treated with cefaclor during 1977 were tested by disk diffusion only; these strains were maintained in blood broth after primary isolation until tested. Susceptibility tests. Stored strains were revived by growth in Todd-Hewitt blood broth (Difco) and were tested for purity by subculturing onto sheep blood agar plates. Minimal inhibitory concentrations (MICs) were determined according to the recommendations of the International Collaborative Study (6), using twofold dilutions of antibiotic in Mueller-Hinton agar (BBL). Cefaclor and cephalothin were kindly provided by Eli Lilly & Co. Inocula were prepared from overnight Mueller-Hinton broth cultures, transferred to fresh broth, and incubated for several hours to insure log-phase growth. The latter were diluted to an optical density that insured a 104 CFU inoculum per pin using a multipoint inoculator. Plates were incubated in air at 37°C for 18 h.
Disk diffusion testing was performed on MuellerHinton agar using inocula of 108 CFU/ml from broth cultures. Penicillin (10 U), cefaclor (30,ug), and cephalothin (30 jg) disks were used; the cefaclor disks were prepared for Eli Lilly & Co. by BBL by using a new crystalline process (7) . Inoculated plates were allowed to dry for 30 min before applying disks, and then were incubated as above.
Clinical study. Eighty patients with staphylococcal bullous impetigo were enrolled in a clinical investigation during the summer of 1977 to determine the efficacy of cefaclor for this infection; 73 were evaluated after beginning therapy. All were seen by one of us (H.C.D.) in the Skin Infections Clinic at The Children's Hospital, Birmingham, Ala. Informed consent was obtained from parents. The patients ranged in age from 1 to 13 years, with a mean age of 4.3 years. Fiftyseven per cent were males and 93% were black. Character and severity of the skin infections were defined, and lesion cultures were obtained as previously described (4 positive in 12 of them. Lesions in five of seven patients first evaluated after 6 treatment days were completely cleared; the remaining two were those later proven to be treatment failures. In general, therapeutic outcome was usually predictable by the 4th or 5th day. Treatment was discontinued after 5 days in a 1-year-old infant who developed diarrhea at which time his lesions were healed. The diarrhea promptly subsided. One other patient voluntarily discontinued treatment after 5 days, at which time healing was complete. He remained well.
Cefaclor suspension was reported to be palatable and was well received. No nausea or vomiting occurred. Laboratory parameters, determined in 65 patients, revealed no changes suggestive of drug-induced toxicity.
DISCUSSION
The in vitro data revealed that most staphylococci were suceptible to both cefaclor and cephalothin. However, strains from children, including all sources, were less often resistant than were those from hospitalized adults. This may reflect in part differences in pattern of use of the cephalosporin drugs in the two populations.
In previously reported in vitro studies, several methods were employed, including agar dilution (1, 9), broth dilution (8, 11, 12), or both (11).
With one exception (11) , MIC values obtained with an inoculum of 104 colony-forming units of S. aureus were similar and agree with results presented here.
Two of the above-mentioned studies presented data for both disk and dilution methods on a combined total of 70 S. aureus strains. Discrepancies (over-predicting susceptibility) were noted in both (8, 12) . Our own results with 198 strains revealed the cefaclor disk to be reliable for detecting susceptible strains but discrepanicies were observed, notably among those with an MIC equal to or greater than 16. With the latter, the disk commonly over-predicted susceptibility. The observed differences in zone sizes with cefaclor and cephalothin made it apparent that the use of the latter disk would result in even greater error for over-predicting cefaclor susceptibility. Shadomy and Carver recently reported their findings comparing cephalothin and cefaclor disk diffusion tests; most strains examined were gram negatives (10) . They concluded that the cephalothin disk under-predicted susceptibility of gram-negative species for cefaclor and, like our findings, over-predicted susceptibility to gram-positive species. It thus appears that some modification may be required to insure proper clinical interpretation of cefaclor susceptibility by the disk method. Appropriate zone size ranges for susceptibility must be established for individual species of organisms.
Strains causing skin infection are of special interest because of the perennial problem of bullous impetigo among children in this community. In three collections of impetigo strains examined, the incidence of penicillin resistance increased from 48 (1966) to 94% by 1977. The preferred treatment for bullous impetigo is an orally administered antibiotic suitable for ambulatory patients. In vitro examination of staphylococci from patients with skin infection suggested that cefaclor should prove suitable for such infections. Clinical results now reported confirmed the efficacy of cefaclor in terms of the overall cure rate, eradication of staphylococci, and rapid clearing of skin lesions. Clinical trials in which cefaclor can be compared to other cephalosporins active when administered orally should ultimately determine the usefulness of this newer antibiotic.
